ACCESS PHARMACEUTICALS CEO INTERVIEWED ON FINANCIA
Call Offered Executive Summary and Perspective on Business Strategy
06.25.2009 – DALLAS, June 25, 2009 -- ACCESS PHARMACEUTICALS, INC. (OTC
Bulletin Board: ACCP) announced today that Mr. Jeffrey Davis, Chief Executive Officer
and Mr. David Luci, Director and Consultant, were recently interviewed by
StocksHaven.com, a financial website. The hour-long call was to provide an
executive summary, along with an overview and update of the Access
Pharmaceuticals’s business strategy. Mr. Davis shed light on acquisitions,
partnerships, current and future plans, and also discussed preparations to re-rejoin
a major exchange. The interview is currently featured on the website at
"We are pleased to be featured by StocksHaven Investments," commented Mr.
Davis. "As we continue to build upon our business, now is an opportune time to
learn about Access and we are glad to share our exciting investment thesis with
financial websites that offer investors new and upcoming investment ideas."
StocksHaven.com is a website which hosts services for StocksHaven Investments.
The website contains a blog, free level 2 quotes, discussion forum, stock research
reports, conference calls, investment dictionary, news feeds, videos, stock
commentaries, company reviews and other unique content including expert stock
analysis from Michael Vlaicu.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that
develops and commercializes propriety products for the treatment and supportive
care of cancer patients. Access' products include ProLindac™, currently in Phase 2
clinical testing of patients with ovarian cancer, and MuGard™ for the management of
patients with mucositis. The company also has other advanced drug delivery
technologies including Cobalamin™-mediated targeted delivery and oral drug
delivery, its proprietary nanopolymer delivery technology based on th